靶向阻断表皮生长因子受体信号通路影响鼻咽癌细胞生长的研究

Blocking epidermal growth factor receptor signal pathway to inhibit cell growth of nasopharynx cancer

目的:利用Erlotinib(厄洛替尼,EGFR-酪氨酸激酶拮抗剂,商品名tarceva)阻断表皮生长因子受体(EGFR)介导的信号通路,观察其对鼻咽癌细胞株CNE-2生长的影响,并探索其机制。方法:用不同浓度Erlotinib处理鼻咽癌细胞株CNE-2,采用Cell Count Kit-8(CCK-8)法检测细胞生长抑制率,流式细胞术进行细胞周期、凋亡率的分析,Western bloting检测相关蛋白表达。结果:(1)Erlotinib呈剂量依赖性抑制CNE-2细胞生长;(2)处理组细胞G1期细胞比例和凋亡率明显高于对照组(P<0.05);(3)与对照组相比,处理组出现明显的p-EGFR表达下调。结论:Erlotinib通过抑制EGFR的磷酸化阻断EGFR信号通路,增加G1期阻滞,从而抑制鼻咽癌细胞生长。

Objective To study the effect of Erlotinib, an EGFR-selectivetyrosine kinase inhibitor, on cell proliferance of nasopharyngeal cancer （NPC） by blocking epidermal growth factor receptor （EGFR） signal pathway. Methods NPC cell line, CNE-2, was used to be incubated by Erlotinib at different concentrations. Cell growth, cell cycle progression, apoptosis of CNE-2 and target protein expression were detected by cell growth assay, flow cytometric analysis assay and Western blotting assay, respectively. Results （1）Erlotinib could inhibit the growth of CNE-2 in does-dependent manner. （2） The levels of G1 arrest and apoptosis of CNE-2 in Erlotinib group were obvious higher than those in control group（P 〈 0.05）. （3）The p-EGFR level was reduced in Erlotinib group compared with the control group. Conclusion Erlotinib can inhibit cell growth of CNE-2 by blocking EGFR signal pathway and increasing G1 arrest.